Evidence map›Paper›PMID 39264603›Full record

ArticleTranslational vision science & technology2024

Effects of Telmisartan on Intraocular Pressure, Blood Pressure, and Ocular Perfusion Pressure in Normal and Glaucomatous Cats.

Kazuya Oikawa, Julie A Kiland, Virginia Mathu, Odalys Torne, Colton Wickland, Sarah Neufcourt, Chloë Mitro, Ryan Lopez, Gillian J McLellan

Abstract read
In one paragraph

Article in Translational vision science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuya OikawaSurgical Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Julie A KilandOphthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Virginia MathuSurgical Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Odalys TorneSurgical Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Colton WicklandOphthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Sarah NeufcourtOphthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Chloë MitroOphthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Ryan LopezOphthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.
Gillian J McLellanSurgical Sciences, University of Wisconsin-Madison, Madison, WI, USA.

Funding

UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI Donna M Peters · 2005 to 2026
$12.6M
Therapeutic Inhibition of Optic Nerve Head Gliosis and Fibrosis in GlaucomaR01EY027396 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI MCLELLAN, GILLIAN JANE · 2017 to 2021
$2.0M
NEI NIH HHS P30 EY016665NEI NIH HHS R01 EY027396
6 · The paper itself

Abstract

Purpose: To determine the effect of telmisartan on intraocular pressure (IOP), blood pressure (BP), and ocular perfusion pressure (OPP) in normal and glaucomatous cats. Methods: A four-week study was conducted in six normal adult cats, followed by a longer six-month study performed in 37 cats with spontaneous glaucoma and 11 age-matched normal cats. Telmisartan (1 mg/kg/day) or placebo-vehicle were administered orally once daily. IOP was measured by rebound tonometry. BP readings were obtained by oscillometric method. OPP was calculated as mean arterial pressure (MAP) - IOP. IOP and BP were obtained three times a week for the first study and weekly for the second study. Results: Baseline IOP was significantly higher, and OPP was significantly lower in glaucomatous cats than in normal cats (P < 0.0001). These differences between glaucomatous and normal cats persisted throughout the study, regardless of treatment (P < 0.001). No significant differences in IOP, BP, or OPP were detected between any study phases in the first, normal feline cohort or between telmisartan- and placebo-treated glaucomatous cats at any timepoint in the second study. Conclusions: Oral telmisartan was well tolerated and did not have a detrimental effect on BP or OPP in cats but did not lower IOP or improve OPP in cats with glaucoma. Translational Relevance: While showing telmisartan could not be used as a sole therapy for IOP lowering, our data affirmed a lack of detrimental effects of telmisartan on BP and OPP in a translationally-relevant, spontaneous, large animal glaucoma model.

Indexed as

Angiotensin II Type 1 Receptor BlockersBlood PressureIntraocular PressureTelmisartanAdministration, OralAnimalsBenzimidazolesBenzoatesCatsDisease Models, AnimalFemaleGlaucomaMaleTonometry, OcularAngiotensin II Type 1 Receptor BlockersBenzimidazolesBenzoatesTelmisartan

Identifiers

PMID39264603
PMCPMC11407481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.